ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 175 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,653 | -72.8% | 411 | -64.8% | 0.00% | -80.0% |
| Q2 2023 | $53,834 | +0.9% | 1,167 | -12.3% | 0.01% | -16.7% |
| Q1 2023 | $53,333 | +24.6% | 1,330 | +43.9% | 0.01% | +20.0% |
| Q4 2022 | $42,809 | +137.8% | 924 | +111.4% | 0.01% | +150.0% |
| Q3 2022 | $18,000 | +80.0% | 437 | +155.6% | 0.00% | +100.0% |
| Q2 2022 | $10,000 | +900.0% | 171 | +677.3% | 0.00% | – |
| Q1 2022 | $1,000 | -80.0% | 22 | -62.7% | 0.00% | -100.0% |
| Q4 2021 | $5,000 | +150.0% | 59 | +136.0% | 0.00% | – |
| Q3 2021 | $2,000 | – | 25 | +733.3% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 3 | -94.7% | 0.00% | -100.0% |
| Q1 2021 | $6,000 | – | 57 | +1325.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 4 | -97.1% | 0.00% | -100.0% |
| Q3 2019 | $5,000 | 0.0% | 136 | +44.7% | 0.00% | -66.7% |
| Q1 2016 | $5,000 | -16.7% | 94 | +70.9% | 0.00% | -25.0% |
| Q4 2015 | $6,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |